Pfizer's Upjohn Unit Combined With Mylan to Form Viatris

Pfizer (NYSE: PFE), a multinational pharmaceutical company, completed the spin off of its Upjohn business unit which subsequently combined with Mylan N.V., a European pharmaceutical firm, to form Viatris (Nasdaq: VTRS) in a transaction valued at $12 billion.

Morrow Sodali acted as the information agent for the bidder in this transaction.

Find more information here.